Publications by authors named "L Galvez-Benitez"
Background: Antimicrobial resistance is a critical global health issue, significantly contributing to patient mortality. Recent antibiotic developments have aimed to counteract carbapenemase-producing Enterobacterales; however, the impact of their use on the emergence of antibiotic resistance is unknown. This study investigates the first case of a non-carbapenemase-producing, pan-β-lactam-resistant Escherichia coli strain from a patient previously treated with ceftolozane-tazobactam and cefiderocol.
View Article and Find Full Text PDFObjectives: The BIChromET selective medium for detecting piperacillin-tazobactam (TZP) and cefepime (FEP) resistant was developed.
Methods: The performance of this medium was first evaluated using a collection of 100 clinical strains (70 TZP-susceptible, 30 TZP-resistant, 58 FEP-susceptible, and 42 FEP-resistant). Then, we performed clinical validation by testing 173 respiratory clinical samples.
Piperacillin-tazobactam resistance (P/T-R) is increasingly reported among Escherichia coli isolates. Although in vitro experiments have suggested that bla gene plays a key role in the P/T-R acquisition, no clinical in vivo study has yet confirmed the role of bla or other genes. Therefore, we aimed to identify the mechanisms underlying P/T-R by following up patients with E.
View Article and Find Full Text PDFObjective: To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 - 2020.
Methods: Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints.
Article Synopsis
- Excessive use of piperacillin/tazobactam (P/T) has led to the rise of P/T-resistant bacterial strains, complicating treatment options.
- To address slow conventional testing methods, researchers developed MALDIpiptaz, a quick and affordable test using MALDI-MS technology to detect P/T resistance in bacterial isolates.
- Results showed MALDIpiptaz can rapidly differentiate between P/T-resistant, ESRI developer, and P/T-susceptible isolates within 15 minutes, making it a promising tool for clinical diagnostics.